Universal Study Design for Instrument Changes in Pharmaceutical Release Analytics
Key Learning Outcomes
- Understand why instrument comparability studies are essential in regulated QC release analytics, what risk assessment framework should support them, and how the three potential outcomes: seamless transition, partial revalidation, or full revalidation align with the ICH Q2 lifecycle change categories.
- Learn how to systematically identify the seven instrument performance parameters that must be evaluated for profile-based analytical methods: sensitivity, proportionality, baseline comparability, peak position, resolution, peak area, and measurement variance, and how each correlates with a specific experimental protocol.
- Discover how historical QC data, including control chart data collected over years by multiple analysts, can be utilised to set statistically robust acceptance criteria for new instrument qualification, avoiding redundant experiments on the old instrument altogether.
- Explore how a single, well-designed comparability study using the most complex product and sample preparation can act as a universally indicative benchmark across multiple affected products, maximising efficiency in a GMP QC environment.
Event Overview
This session by Dr Anne Reis introduces a universally applicable study design for managing instrument changes in pharmaceutical QC release analytics, a highly practical yet often overlooked challenge in analytical lifecycle management. Based on a real-world benchmark involving the transition from one icIEF instrument platform to another across five commercial products, the presentation provides a comprehensive, data-driven framework that is both scientifically rigorous and GMP-compliant.
The session begins by outlining the main challenge: when an instrument needs replacing due to vendor support ending, platform becoming obsolete, or other reasons, the laboratory requires a logical, data-driven basis to evaluate performance differences and decide the suitable regulatory approach. The three possible outcomes are outlined at the start: smooth continuation without revalidation, targeted partial revalidation, or full revalidation with the study design guiding the decision-making process.
The foundational theory of the study design is then systematically established. Instead of performing a gap assessment of instrument specifications, the focus remains on what truly matters: the analytical readout. For profile-based methods such as capillary electrophoresis and chromatography, seven parameters are identified: three on the signal axis, two on the separation axis, the peak area, and measurement variance, each of which must be considered to confirm that the new instrument is truly equivalent.
The experimental design is efficient and elegant. Historical control chart data from the old instrument in the benchmark case, comprising over 120 data points collected across four years, are used to establish acceptance criteria, offering statistical power that no prospective study can match. Only two experiments are conducted on the new instrument: a response experiment replicating the original validation protocol, and a matrix experiment designed similarly to an intermediate precision study. The most complex product in the portfolio is chosen as the primary test case, making the results representative for all other related products.
The session concludes with the benchmark results, with all seven parameters passing, enabling a seamless transition of four out of five products to the new instrument and offering a broader reflection on the transferability of the study design to chromatographic and other profile-based methods across the industry.
Who Should Attend?
Anyone involved in analytical method lifecycle management, instrument qualification, or QC release analytics seeking a practical, GMP-compliant framework for handling instrument changes without undue revalidation efforts.
- Analytical Scientists and Method Development Chemists in QC and development settings
- Quality Control and Quality Assurance Professionals
- Validation and Compliance Scientists
- Regulatory Affairs and CMC Submission Specialists
- Laboratory Managers and Directors overseeing release analytics
- Analytical Technology and Instrument Specialists
- R&D and Technical Operations Managers overseeing analytical lifecycle management
Unlock Additional Educational Resources
Register today for Anne’s presentation and gain access to exclusive bonus content, such as the insightful panel discussion on “Best Practices for Updating Analytical Procedures in Drug Development and Manufacturing”.
Anne Ries, PhDScientist in Analytical Sciences and TechnologiesBoehringer Ingelheim (Germany)Anne Ries joined Boehringer Ingelheim in 2022. She works on various lifecycle topics in pharmaceutical release analytics, focusing on innovation during the post-approval phase of a biopharmaceutical product. Anne aims for efficient and digital solutions, as well as public accessibility and exchange across companies. Anne holds a biochemistry degree from the University of Tübingen, Germany, and completed her PhD in structural biology at ETH Zürich, Switzerland.
| Presenter |
|
Brought to you by:
